Clarius Group LLC Makes New $410,000 Investment in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Clarius Group LLC bought a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 657 shares of the biopharmaceutical company’s stock, valued at approximately $410,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Platte River Wealth Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $296,000. Private Trust Co. NA bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $349,000. Anderson Hoagland & Co. bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $998,000. State of Alaska Department of Revenue grew its holdings in shares of Regeneron Pharmaceuticals by 164.6% in the 2nd quarter. State of Alaska Department of Revenue now owns 36,344 shares of the biopharmaceutical company’s stock valued at $22,665,000 after acquiring an additional 22,607 shares in the last quarter. Finally, Ellevest Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 437.9% in the 2nd quarter. Ellevest Inc. now owns 156 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 127 shares in the last quarter. Hedge funds and other institutional investors own 68.04% of the company’s stock.

Shares of Regeneron Pharmaceuticals stock opened at $640.34 on Thursday. The firm has a market cap of $70.51 billion, a PE ratio of 32.18, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. Regeneron Pharmaceuticals Inc has a 12-month low of $271.37 and a 12-month high of $653.53. The company has a quick ratio of 3.49, a current ratio of 4.21 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $601.82 and its two-hundred day simple moving average is $486.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $6.13 by $0.47. The firm had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.81 billion. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period last year, the company posted $4.45 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals Inc will post 23.48 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 5,497 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $521.07, for a total transaction of $2,864,321.79. Following the transaction, the executive vice president now owns 24,459 shares of the company’s stock, valued at $12,744,851.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert E. Landry sold 828 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $509.79, for a total transaction of $422,106.12. Following the transaction, the chief financial officer now directly owns 27,873 shares in the company, valued at approximately $14,209,376.67. The disclosure for this sale can be found here. Insiders have sold 217,927 shares of company stock valued at $125,546,741 over the last 90 days. 11.84% of the stock is currently owned by company insiders.

Several equities analysts have recently weighed in on REGN shares. Wolfe Research began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They issued a “market perform” rating and a $455.00 price objective for the company. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $409.00 to $555.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. SVB Leerink raised their target price on shares of Regeneron Pharmaceuticals from $622.00 to $625.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Goldman Sachs Group raised their target price on shares of Regeneron Pharmaceuticals from $636.00 to $700.00 and gave the company a “conviction-buy” rating in a research note on Wednesday, May 6th. Finally, Royal Bank of Canada cut their target price on shares of Regeneron Pharmaceuticals from $533.00 to $524.00 in a research note on Wednesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $565.64.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: Which market index is the best?

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.